Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update
OLPRUVA™ is not used to treat rapid increase of ammonia in the blood (acute hyperammonemia), which can be life-threatening and requires emergency medical treatment.
- OLPRUVA™ is not used to treat rapid increase of ammonia in the blood (acute hyperammonemia), which can be life-threatening and requires emergency medical treatment.
- As a result, Acer is pausing the ACER-801 program until Acer has conducted a thorough review of the full data set
Ended Q4 2022 with $2.3 million in cash and cash equivalents. - Cash and cash equivalents were $2.3 million as of December 31, 2022, compared to $12.7 million as of December 31, 2021.
- For additional information, please see Acer’s Annual Report on Form 10-K filed today with the SEC.